Study of SPG601 in Adult Men With Fragile X Syndrome

Phase 2 Completed 10 enrolled Spinogenix Avance Clinical Pty Ltd. · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.

Timeline

Start: 2024-07-05
Primary completion: 2024-12-31
Completion: 2024-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	SPG601	Small molecule	800 mg	Oral

Study of SPG601 in Adult Men With Fragile X Syndrome

Summary

Timeline

Drugs

Indications